Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 4,121.8 | 3,764.8 | 3,017.8 | 2,957.2 | 2,965.1 | 2,845.7 | 2,780.6 | 4,616.4 |
| Revenue growth | 9.5% | 24.8% | 2.0% | -0.3% | 4.2% | 2.3% | -39.8% | -1.1% |
| Cost of goods sold | 2,757.2 | 2,445.6 | 1,960.2 | 1,905.7 | 1,917.4 | 1,858.2 | 1,821.5 | 3,017.6 |
| Gross profit | 1,364.6 | 1,319.2 | 1,057.6 | 1,051.5 | 1,047.7 | 987.5 | 959.1 | 1,598.8 |
| Gross margin | 33.1% | 35.0% | 35.0% | 35.6% | 35.3% | 34.7% | 34.5% | 34.6% |
| Selling, general and administrative | 677.1 | 596.4 | 520.5 | 540.1 | 534.3 | 536.0 | 531.4 | 884.0 |
| Research and development | 92.2 | 85.9 | 75.7 | 78.9 | 76.7 | 73.2 | 73.3 | 98.7 |
| EBITA | 647.6 | 670.2 | 499.5 | 464.2 | 471.6 | 414.7 | 389.8 | 685.7 |
| EBITA margin | 15.7% | 17.8% | 16.6% | 15.7% | 15.9% | 14.6% | 14.0% | 14.9% |
| Amortization of intangibles | 52.5 | 26.3 | 28.4 | 31.7 | 34.9 | 36.4 | 35.4 | 68.1 |
| EBIT | 595.1 | 643.9 | 471.1 | 432.5 | 436.7 | 378.3 | 354.4 | 617.6 |
| EBIT margin | 14.4% | 17.1% | 15.6% | 14.6% | 14.7% | 13.3% | 12.7% | 13.4% |
| Pre-tax income | 550.6 | 626.8 | 432.1 | 407.5 | 379.8 | 172.8 | 220.9 | 512.5 |
| Income taxes | 67.4 | 70.8 | 75.0 | 45.8 | 58.1 | 58.7 | 42.7 | 115.4 |
| Tax rate | 12.2% | 11.3% | 17.4% | 11.2% | 15.3% | 34.0% | 19.3% | 22.5% |
| Earnings from continuing ops | 483.2 | 1,109.0 | 358.6 | 717.4 | 347.4 | 485.4 | 521.6 | 327.4 |
| Earnings from discontinued ops | -2.3 | 0.0 | 0.0 | 0.0 | 0.0 | 181.1 | 0.6 | -6.7 |
| Net income | 480.9 | 1,109.0 | 358.6 | 717.4 | 347.4 | 666.5 | 522.2 | 320.7 |
| Net margin | 11.7% | 29.5% | 11.9% | 24.3% | 11.7% | 23.4% | 18.8% | 6.9% |
| |
| Diluted EPS | $2.92 | $6.62 | $2.14 | $4.21 | $1.96 | $2.64 | $2.85 | $1.79 |
| Shares outstanding (diluted) | 165.6 | 167.5 | 167.4 | 170.4 | 177.3 | 183.7 | 183.1 | 182.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|